Immunization of HIV-infected adults with a three-dose series of inactivated Mycobacterium vaccae.
Heat-killed Mycobacterium vaccae vaccine was administered in a 3-dose schedule to 12 HIV-infected adults with CD4 cell counts > or = 300/mm3. Local and systemic side effects were monitored. Delayed-type hypersensitivity to purified protein derivative and Mycobacterium avium sensitin was measured at baseline and after the final dose. Antibody to aralipoarabinomannin, man-lipoarabinomannin, and a short-term culture filtrate of Mycobacterium tuberculosis were also measured. Lymphocyte proliferation responses to M avium sensitin and M vaccae sonicate were determined. Vaccine site induration was maximal at 2 days (median, 6 mm) and no systemic side effects were noted. Purified protein derivative skin test conversions did not occur. Changes in CD4 counts and HIV viral load were not significant. Three (27%) of 11 subjects who completed the trial showed either M avium skin test (n = 1) or short-term culture filtrate antibody (n = 2) responses. A three-dose schedule of M vaccae vaccine is safe and well tolerated in adults with early HIV infection and produces detectable immunologic responses in a subset of these subjects.
Marsh
B J
BJ
Infectious Disease Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
Fordham von Reyn
C
C
Arbeit
R D
RD
Morin
P
P
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000328:Adult; D001428:Bacterial Vaccines; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D006968:Hypersensitivity, Delayed; D008213:Lymphocyte Activation; D008875:Middle Aged; D009161:Mycobacterium / Q000276:immunology*; D009164:Mycobacterium Infections / Q000517:prevention & control*; D015269:Mycobacterium avium Complex / Q000276:immunology; D015270:Mycobacterium avium-intracellulare Infection / Q000517:prevention & control*; D009169:Mycobacterium tuberculosis / Q000276:immunology; D015164:Vaccines, Inactivated
D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated